



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/695,680	10/29/2003	James Frederick Harrington JR.	21486-056	5034

7590 06/14/2007
Ingrid A. Beattie, Ph.D., J.D.
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111

EXAMINER

RAMACHANDRAN, UMAMAHESWARI

ART UNIT	PAPER NUMBER
----------	--------------

1617

MAIL DATE	DELIVERY MODE
-----------	---------------

06/14/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/695,680

Applicant(s)

HARRINGTON, JAMES
FREDERICK

Examiner

Umamaheswari Ramachandran

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 29 March 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-21 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

Art Unit: 1617

DETAILED ACTION

Response to Remarks

The examiner notes the receipt of the amendments and remarks received in the office on 3/29/2007. Claims 1, 10, 14, 16, 17 have been amended and 21 have been added new. Claims 1-21 are pending.

Applicant's response to the rejection of claims 1-13,15,16,19-20 rejected under 35 U.S.C 103(a) have been considered and the amendment of claims 1, 10, 16, 17 necessitated the new rejection. Applicant's response to the rejection of claim 18 rejected under 35 U.S.C 103(a) have been considered and the amendment of claims 1, 10, 16, 17 necessitated the new rejection. Applicant's response to the rejection of claim 14 rejected under 35 U.S.C 103(a) have been considered and the amendment of claim 14 necessitated the new rejection. The objection of claim 17 is withdrawn and upon further consideration the new rejection has been made. Hence the office action is made non-final.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-7, 12, 13-17,19-20, 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Harrington et al. (Spine. 2000 Apr 15;25(8):929-36) in view of Lawand et al. (Euro J of Pharmacology, 324, (1997), 169-177).

Harrington et al. teaches that disc radiculopathy can be treated with epidural glutamate receptor antagonists. The reference teaches that herniated or degenerated disc material contains free glutamate material that acts locally at the dorsal root ganglion to potentiate pain signals (p 935, key points). The reference further teaches that the injections of glutamate receptor antagonists may be beneficial in the radicular pain and other types of spinal pain (p935, lines 13-15). The reference further teaches that administration of intravenous glutamate antagonists can lessen pain responses and intrathecal delivery of glutamate antagonists can attenuate pain behavior (p 934, col. 2, lines 20-26). The reference also teaches that disc radiculopathy may be treated with epidural glutamate receptor antagonists (see Abstract). It is obvious that administration of glutamate receptor antagonists binds to the glutamate receptors and inhibits the binding of free glutamate.

The reference does not teach a tear in a disc annulus and the administration of glutamate antagonist directly to said herniated disc tissue.

It would have been obvious to one of ordinary skill in the art at the time of the invention to administer glutamate antagonist directly to said herniated disc tissue. Annulus tears can be a precursor of herniated disc or damage by tear can cause herniated disc. Harrington teaches that glutamate originating from degenerated disc may diffuse to the dorsal root ganglion and effect glutamate receptors and that local injections of glutamate receptor antagonist may be beneficial in the treatment of radicular pain and other types of spinal pain. Hence it would have been obvious to one of ordinary skill in the art at the time of the invention to administer glutamate antagonist

Art Unit: 1617

directly to said herniated disc tissue to relieve radicular pain and spinal pain as taught by Harrington.

The reference does not teach an ionotropic glutamate receptor or NMDA type receptor antagonist in a method to alleviate pain in mammal.

Lawand et al. teaches the intra-articular injection in knee joint of either an NMDA or a non-NMDA glutamate receptor (CNQX) attenuated the thermal hyperalgesia and the mechanical allodynia produced by glutamate, arginine and aspartate (see Abstract). This addresses claims 2-4, 7, 12, 15, 16 and 20. The reference also teaches that the administration of MK-801 reduced the induced thermal hyperalgesic response (p 174, col. 2, lines 26-27) and thus addresses claims 5 and 6. The reference further teaches that attenuation of pain related behavior by intra-articular application of NMDA and non-NMDA excitatory amino acid antagonists after full development of the knee joint inflammation suggests a novel and viable alternative for pharmacological reduction of joint pain associated with inflammation (p 177, col. 2-7).

It would have been obvious to one of ordinary skill in the art at the time of the invention to administer ionotropic glutamate receptor or NMDA type receptor antagonist in a method to alleviate pain in mammal. The motivation to do so is taught by Harrington and Lawland et al. Harrington teach the release of free glutamate ions in disc degeneration and further teaches that local injections of glutamate receptor antagonist may be beneficial in the treatment of radicular pain. Lawland teach that intra-articular injection in knee joint of either an NMDA or a non-NMDA glutamate receptor (CNQX) attenuated the thermal hyperalgesia and the mechanical allodynia produced by

Art Unit: 1617

glutamate. Hence one of ordinary skill in the art would have been motivated to administer such compounds to alleviate pain by inhibition of binding of free glutamate released (such as lumbar radioculopathy).

The references do not teach a method of alleviating pain in the elbow joint tissue of a mammal comprising administering a glutamate receptor antagonist.

It would have been obvious to one of ordinary skill in the art at the time of the invention to administer a glutamate receptor antagonist in a method to alleviate pain in the elbow joint tissue. The motivation to do so is taught by Lawland. The reference teaches that attenuation of pain related behavior by intra-articular application of NMDA and non-NMDA excitatory amino acid antagonists after full development of the knee joint inflammation suggests a novel and viable alternative for pharmacological reduction of joint pain associated with inflammation (p 177, col. 2-7). Elbow joint is another joint like knee joint and hence one of ordinary skill in the art would have been motivated to alleviate the pain in the elbow joint by administration of glutamate receptor antagonists as Lawland teaches the NMDA and non-NMDA antagonists role in attenuation of pain in knee joint inflammation.

Claim 18 is rejected under 35 U.S.C 103(a) as being unpatentable over Harrington et al. (Spine. 2000 Apr 15;25(8):929-36) in view of Lawand et al. (Euro J of Pharmacology, 324, (1997), 169-177) as applied to claims 1-7, 12, 13-17,19-20, 21 above and in view of Takahashi et al. (Pain, 75 (1998), 391-394).

Harrington and Stanfa et al.'s teachings discussed as above.

Art Unit: 1617

Harrington and Stanfa et al. do not teach an epidural administration of glutamate receptor antagonist.

Takahashi teaches the epidural administration of NMDA receptor antagonist ketamine to relieve neuropathic pain (see Abstract).

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to develop a method of treatment to alleviate pain by administering glutamate receptor antagonist epidurally as Takahashi teaches a low dose of administration of NMDA receptor antagonist is sufficient to block activated NMDA receptors in dorsal horn neurons and is an effective choice for the management of neuropathic pain without any undesirable side effects (p 394, col. 1, lines 12-16).

Claims 1, 8, 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Harrington et al. (Spine. 2000 Apr 15;25(8):929-36) as applied to claims 1-7, 12, 13-17, 19-20, 21 above and in view of Stanfa et al. (Neuroscience, 1999, vol. 93, No. 4, p 1391-1398).

Harrington et al. teachings discussed as above.

The reference does not teach a method of alleviating pain by administering KA receptor antagonists and binding of free glutamate to mGlu2 receptor.

Stanfa et al. teaches the administration of non-NMDA receptor antagonists NBQX (AMPA, Glu R1-4 subunit) and LY383884, a KA receptor antagonist directly to the spinal cord of rats (col. 1, p 1392). The reference teaches the enhanced role of AMPA and Kainate antagonists in spinal nociceptive processing in inflammatory states (see Abstract) thus addressing claims 8 and 11.

Art Unit: 1617

It would have been obvious to one skilled in the art to use KA receptor antagonists in a method of treatment to alleviate pain. The motivation to do is provided by Harrington et al. and Stanfa et al. Stanfa et al. teaches the enhanced role of AMPA and Kainate antagonists in spinal nociceptive processing in inflammatory states. Harrington teaches the release of free glutamate ions in disc degeneration and further teaches that local injections of glutamate receptor antagonist may be beneficial in the treatment of radicular pain. Hence one of ordinary skill in the art would have been motivated to administer a KA receptor antagonist compound to alleviate pain by inhibition of binding of free glutamate released in conditions like herniated disc.

Claims 1, 9, 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Harrington et al. (Spine. 2000 Apr 15;25(8):929-36) as applied to claims 1-7, 12, 13-17, 19-20, 21 above and in view of Garrett (Biol. Res. for Nursing, Vol. 1, No. 4, Apr 2000).

The reference does not teach a method of alleviating pain by administering metabotropic glutamate receptor antagonists.

Garrett teaches that L-AP3 a metabotropic glutamate receptor antagonist exhibited an antinociceptive effect in animals linking effective treatment of hyperalgesia with metabotropic glutamate receptor (p 316, col. 2, lines 5-9). This addresses claims 9 and 10.

It would have been obvious to one skilled in the art to use metabotropic glutamate receptor antagonists in a method of treatment to alleviate pain. The motivation to do is provided by Harrington and Garrett. Garrett teaches the crucial role of

Art Unit: 1617

excitatory amino acid, glutamate, NMDA and non-NMDA receptors in pain transmission, pain modulation, central sensitization and the sensation of hyperalgesia (see Abstract, p 311, col. 1, lines 15-44). The reference further teaches that L-AP3 a metabotropic glutamate receptor antagonist exhibited an antinociceptive effect in animals linking effective treatment of hyperalgesia. Harrington teaches the release of free glutamate ions in disc degeneration and further teaches that local injections of glutamate receptor antagonist may be beneficial in the treatment of radicular pain. Hence one of ordinary skill in the art would have been motivated to administer a metabotropic glutamate receptor antagonist in conditions like degenerated disc to alleviate pain by inhibition of binding of free glutamate released.

Conclusion


No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Umamaheswari Ramachandran whose telephone number is 571-272-9926. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER